Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville (Y.H.K., S.-w.C., S.P.O.).
Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ (Y.H.K., S.P.O.).
Circ Res. 2020 Oct 9;127(9):1122-1137. doi: 10.1161/CIRCRESAHA.119.316267. Epub 2020 Jul 31.
Hereditary hemorrhagic telangiectasia (HHT) is a genetic disease caused by mutations in , , or . Since proteins from all 3 HHT genes are components of signal transduction of TGF-β (transforming growth factor β) family members, it has been hypothesized that HHT is a disease caused by defects in the ENG-ALK1-SMAD4 linear signaling. However, in vivo evidence supporting this hypothesis is scarce.
We tested this hypothesis and investigated the therapeutic effects and potential risks of induced-ALK1 or -ENG overexpression (OE) for HHT.
We generated a novel mouse allele (ROSA26) in which HA (human influenza hemagglutinin)-tagged ALK1 and bicistronic eGFP expression are induced by Cre activity. We examined whether ALK1-OE using the ROSA26 allele could suppress the development of arteriovenous malformations (AVMs) in wounded adult skin and developing retinas of - and -inducible knockout (iKO) mice. We also used a similar approach to investigate whether ENG-OE could rescue AVMs. Biochemical and immunofluorescence analyses confirmed the Cre-dependent OE of the ALK1-HA transgene. We could not detect any pathological signs in ALK1-OE mice up to 3 months after induction. ALK1-OE prevented the development of retinal AVMs and wound-induced skin AVMs in -iKO as well as -iKO mice. ALK1-OE normalized expression of SMAD and NOTCH target genes in ENG-deficient endothelial cells (ECs) and restored the effect of BMP9 (bone morphogenetic protein 9) on suppression of phosphor-AKT levels in these endothelial cells. On the other hand, ENG-OE could not inhibit the AVM development in -iKO models.
These data support the notion that ENG and ALK1 form a linear signaling pathway for the formation of a proper arteriovenous network during angiogenesis. We suggest that ALK1 OE or activation can be an effective therapeutic strategy for HHT. Further research is required to study whether this therapy could be translated into treatment for humans.
遗传性出血性毛细血管扩张症(HHT)是一种由 、 或 基因突变引起的遗传病。由于所有 3 种 HHT 基因的蛋白均为 TGF-β(转化生长因子β)家族成员信号转导的组成部分,因此有人假设 HHT 是一种由 ENG-ALK1-SMAD4 线性信号传导缺陷引起的疾病。然而,支持这一假说的体内证据很少。
我们检验了这一假说,并研究了诱导 ALK1 或 ENG 过表达(OE)治疗 HHT 的疗效和潜在风险。
我们生成了一种新型小鼠等位基因(ROSA26),其中 HA(人流感血凝素)标记的 ALK1 和双顺反子 eGFP 的表达由 Cre 活性诱导。我们检测了在 - 和 - 诱导型敲除(iKO)小鼠的伤口愈合成年皮肤和发育中的视网膜中,使用 ROSA26 等位基因的 ALK1-OE 是否可以抑制动静脉畸形(AVMs)的形成。我们还使用类似的方法研究了 ENG-OE 是否可以挽救 AVMs。生化和免疫荧光分析证实了 Cre 依赖性 ALK1-HA 转基因的 OE。在诱导后 3 个月内,我们未在 ALK1-OE 小鼠中检测到任何病理迹象。ALK1-OE 可预防视网膜 AVM 和伤口诱导的皮肤 AVM 在 -iKO 以及 -iKO 小鼠中的形成。ALK1-OE 使 ENG 缺陷的内皮细胞(ECs)中 SMAD 和 NOTCH 靶基因的表达正常化,并恢复了 BMP9(骨形态发生蛋白 9)对这些内皮细胞中磷酸化 AKT 水平的抑制作用。另一方面,ENG-OE 不能抑制 -iKO 模型中的 AVM 发育。
这些数据支持 ENG 和 ALK1 形成一条线性信号通路的观点,该通路在血管生成过程中形成适当的动静脉网络。我们建议 ALK1 OE 或激活可能是治疗 HHT 的有效治疗策略。需要进一步研究以研究该疗法是否可转化为人类治疗。